ADVERTISEMENT

Glenmark Pharma - Divestment Of Life Sciences Arm To Address Short-Term Concerns: ICICI Securities

Glenmark Pharma is divesting 75% stake in its API arm Glenmark Lifesciences for Rs 56.5 billion (Rs 615 per share) to Nirma.

<div class="paragraphs"><p>Glenmark Pharmaceuticals Ltd.'s manufacturing facility (Source: Company website)</p></div>
Glenmark Pharmaceuticals Ltd.'s manufacturing facility (Source: Company website)
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to Unlock & Enjoy your 
Subscriber-Only
 benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit